Approval · Notice of Compliance 13992 · 2013
CAELYX: Notice of Compliance 13992
Issued January 3, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13992
- Date
- January 3, 2013
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition to the manufacturing site; Suspension of eht 50 mg vial production
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAELYX | Not yet assigned | — |
Medicinal ingredients
- DOXORUBICIN HYDROCHLORIDE 2 MG per ML